Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma	B-cell chronic lymphocytic leukemia, B-cell neoplasm, Burkitt lymphoma, Chronic Disease, DNA Virus Infections, Disease Attributes, Epstein-Barr virus infection, Hemic and Lymphatic Diseases, Herpesviridae infectious disease, Infections, Leukemia, B-Cell, Lymphoma, B-Cell, Marginal Zone, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Tumor Virus Infections, diffuse large B-cell lymphoma, follicular lymphoma, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoma, lymphoplasmacytic lymphoma, lymphoproliferative syndrome, mantle cell lymphoma, neoplasm, non-Hodgkin lymphoma, viral infectious disease	Recruiting	Phase 1	2026-06-22		NCT04545762

2 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
C. Babis Andreadis	1
University of California, Davis	257

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
University of California, San Francisco	San Francisco	United States	294